CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 254 filers reported holding CRISPR THERAPEUTICS AG in Q4 2019. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $30,622,000 | +22.0% | 200,000 | -33.3% | 0.73% | -24.5% |
| Q3 2020 | $25,092,000 | -14.6% | 300,000 | -25.0% | 0.96% | -14.0% |
| Q2 2020 | $29,396,000 | +10.0% | 400,000 | -36.5% | 1.12% | -9.7% |
| Q1 2020 | $26,735,000 | -56.1% | 630,400 | -37.0% | 1.24% | -48.9% |
| Q4 2019 | $60,905,000 | +37.0% | 1,000,000 | -7.8% | 2.43% | -10.2% |
| Q3 2019 | $44,445,000 | +34.8% | 1,084,300 | +54.9% | 2.70% | +42.8% |
| Q2 2019 | $32,970,000 | +2.6% | 700,000 | -22.2% | 1.89% | -12.8% |
| Q1 2019 | $32,148,000 | +1025.2% | 900,000 | +800.0% | 2.17% | +836.6% |
| Q4 2018 | $2,857,000 | – | 100,000 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |